Meros Investment Management LP Invests $3.80 Million in MiMedx Group, Inc. (NASDAQ:MDXG)

Meros Investment Management LP acquired a new position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 395,074 shares of the company's stock, valued at approximately $3,801,000. MiMedx Group makes up 1.8% of Meros Investment Management LP's portfolio, making the stock its 29th biggest holding. Meros Investment Management LP owned about 0.27% of MiMedx Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of MDXG. IMG Wealth Management Inc. acquired a new position in shares of MiMedx Group during the 4th quarter worth $28,000. Van ECK Associates Corp acquired a new position in MiMedx Group during the fourth quarter worth about $40,000. Tower Research Capital LLC TRC grew its position in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares during the period. AlphaQuest LLC purchased a new position in MiMedx Group in the fourth quarter valued at about $88,000. Finally, Savant Capital LLC acquired a new stake in shares of MiMedx Group during the 4th quarter valued at approximately $100,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Trading Down 0.6%

NASDAQ MDXG traded down $0.04 during mid-day trading on Friday, hitting $7.05. The company's stock had a trading volume of 614,522 shares, compared to its average volume of 693,020. The firm has a market capitalization of $1.04 billion, a P/E ratio of 12.82 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The stock's fifty day simple moving average is $7.21 and its two-hundred day simple moving average is $8.15.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million. Research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on MDXG shares. StockNews.com downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

Insiders Place Their Bets

In other news, CEO Joseph H. Capper acquired 200,000 shares of the business's stock in a transaction on Friday, May 2nd. The shares were purchased at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now directly owns 529,530 shares of the company's stock, valued at $3,357,220.20. This represents a 60.69% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. This represents a 1.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 in the last 90 days. 1.70% of the stock is owned by company insiders.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.